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Introduction {#sec1}
============

Posttranslational modifications play a key role in the regulation of protein activity, localization, and stability, as well as in the control of protein-protein interactions. Among them, ubiquitylation counts as one of the most prominent and best-characterized modifications. Ubiquitin is a small protein that can be covalently attached to lysine residues of other proteins through the interplay of different ubiquitin-activating (E1) and -conjugating (E2) enzymes and ubiquitin ligases (E3) ([@bib21]). The analysis of mice lacking various components of the ubiquitylation machinery highlighted the importance of ubiquitylation in several cellular and physiological processes, spanning from autophagy, transcription factor regulation, and DNA repair to the control of cell cycle and cell death ([@bib3], [@bib4], [@bib21], [@bib38]), which in turn can affect complex processes such as the immune response ([@bib5], [@bib10]), the maintenance of tissue homeostasis ([@bib29]), and tumorigenesis ([@bib23], [@bib41]).

Life or death cell fate decisions are critical for development, against infectious diseases, or cancer formation. Apoptosis was considered the sole form of programmed cell death during development or disease ([@bib16]). However, besides apoptosis, alternative programmed necrosis or necroptosis can be induced by death receptors ([@bib57]). Survival, apoptosis, and necroptosis can all be triggered by the same cell-surface receptors. There has been intense interest in how these fate decisions are made by identifying the gatekeepers of apoptotic versus necroptotic cell fate and the signaling cascades involved ([@bib9]). One of the most paradigmatic signaling pathways that regulates cellular fate is triggered by the tumor necrosis factor receptor 1 (TNFR1). TNFR1 engagement elicits cell survival pathways via NF-κB induction ([@bib2], [@bib55], [@bib62]). When NF-κB activation is inhibited, TNF stimulation triggers caspase-8-mediated apoptosis via a defined death effector complex ([@bib36], [@bib61]). In specific conditions, blockade of both NF-κB and apoptosis may result in programmed necrotic cell death ([@bib8], [@bib20], [@bib56], [@bib69]). Necroptosis is mediated via the RIP1/RIP3/MLKL kinase pathway and recently has been implicated in normal development and in pathogenesis of diseases, including ischemic injury, neurodegeneration, and intestinal inflammation ([@bib15], [@bib25], [@bib26], [@bib34], [@bib65]).

HECT domain and ankyrin repeat-containing E3 ligase 1 (HACE1) is an E3 ligase initially identified in the context of sporadic Wilms' tumor ([@bib1]). A number of reports showed that HACE1 is downregulated in various types of tumors ([@bib1], [@bib22], [@bib28], [@bib68]), and a previous study from our group highlighted the important function of HACE1 as a tumor suppressor: mice lacking HACE1 showed an increased propensity to develop spontaneous tumors as well as a reduced survival in different cancer models ([@bib68]). In addition to this function, HACE1 has been implicated in Golgi membrane dynamics ([@bib53]), control of oxidative stress ([@bib11], [@bib46]), and heart failure following cardiac injury ([@bib71]). However, the complexity of the molecular and cellular processes potentially regulated by HACE1 is still largely unexplored.

Here we report that HACE1 is a key regulator of TNFR1-mediated cell fate. Genetic inactivation of *hace1* impairs NF-κB activation and apoptosis downstream of TNFR1, whereas RIP3-regulated necroptotic cell fate is not affected. Importantly, we found that *hace1* mutant mice exhibit enhanced intestinal inflammation and colon cancer following epithelial injury, which can be rescued by simultaneous genetic inactivation of either RIP3 or TNFR1.

Results {#sec2}
=======

HACE1 Controls TNFR1-Induced NF-κB Activation {#sec2.1}
---------------------------------------------

To identify pathways relevant to HACE1 function, we scanned the signaling pathways downstream of multiple ligand/receptor pairs, using *hace1* mutant (*hace1*^--/--^) mouse embryonic fibroblasts (MEFs). Intriguingly, *hace1*^--/--^ MEFs stimulated with TNF showed compromised phosphorylation and incomplete degradation of the NF-κB inhibitor IκBα. As a consequence, TNF-induced phosphorylation and activation of the NF-κB subunit p65 was strongly reduced in *hace1*^--/--^ MEFs ([Figure 1](#fig1){ref-type="fig"}A). Impaired NF-κB activation was confirmed using an electrophoretic mobility shift assay (EMSA) filter plate assay ([Figure 1](#fig1){ref-type="fig"}B). Re-expression of wild-type (WT) HACE1 in *hace1*^--/--^ MEFs, but not that of the E3 ligase inactive HACE1 C876S mutant ([@bib1]), restored TNF-induced p65 NF-κB activation ([Figure 1](#fig1){ref-type="fig"}B; [Figure S1](#mmc1){ref-type="supplementary-material"}A). Moreover, TNF-induced NF-κB-dependent expression of interleukin-6 (IL-6) ([@bib6]) also was markedly inhibited in *hace1*-deficient MEFs ([Figure 1](#fig1){ref-type="fig"}C).

In addition to defective NF-κB induction, TNFR1-induced JNK and consequent c-Jun phosphorylation were markedly reduced in *hace1*^--/--^ MEFs, a phenomenon that was accompanied by increased and prolonged ERK1/2 and p38-MAPK phosphorylation ([Figure 1](#fig1){ref-type="fig"}A). TNFR1 and NF-κB are essential for the in vivo clearance of the intracellular pathogen *Listeria monocytogenes* ([@bib45], [@bib48]). Considering the observed in vitro defects in TNFR1/NF-κB activation, we tested whether HACE1 also controls the response to *L. monocytogenes* in vivo. Importantly, we observed impaired clearance of *L. monocytogenes* ([Figure 1](#fig1){ref-type="fig"}D), accompanied by enhanced lethality of the *hace1*^--/--^ mice as compared to their WT littermates ([Figure 1](#fig1){ref-type="fig"}E), a phenotype that is compatible with and might be dependent on defective TNFR1/NF-κB activation. Thus, HACE1 E3 ligase activity is essential for TNF-induced activation of both NF-κB and JNK downstream signaling in vitro, and HACE1 controls in vivo immunity to *L. monocytogenes*.

Impaired TNFR1-Induced Apoptosis in the Absence of HACE1 {#sec2.2}
--------------------------------------------------------

When NF-κB activation is blocked, TNF stimulation results in apoptotic cell death ([@bib2], [@bib55], [@bib61]). Given that TNF-mediated NF-κB activation is impaired in *hace1*^--/--^ cells, we reasoned that loss of HACE1 might sensitize cells to TNFR1-induced apoptosis. Surprisingly, TNF stimulation alone did not induce significant cell death in *hace1*^--/--^ cells ([Figures 2](#fig2){ref-type="fig"}A and 2B), even when we monitored these cells for 72 hr ([Figure S1](#mmc1){ref-type="supplementary-material"}B). Moreover, whereas, as expected, control WT MEFs underwent apoptosis in response to treatment with TNF and actinomycin-D for 8 hr (ActD; used to block NF-κB anti-apoptotic transcriptional activity; [@bib30]), *hace1*^--/--^ MEFs remained resistant to apoptotic death ([Figures 2](#fig2){ref-type="fig"}A and 2B) and cells remained viable, albeit only partially, even at later time points ([Figure S1](#mmc1){ref-type="supplementary-material"}C). Treatment with ActD alone did not induce cell death in control nor *hace1*^--/--^ MEFs ([Figure S1](#mmc1){ref-type="supplementary-material"}D).

Consistent with a critical role for HACE1 in mediating TNF/ActD-induced apoptosis, activation of caspase-8 and its downstream death effector caspase-3 as well as cleavage of RIP1 kinase (RIP1) were markedly impaired in *hace1*^--/--^ MEFs ([Figure 2](#fig2){ref-type="fig"}C). We also failed to detect caspase-3 activation in *hace1*^--/--^ MEFs using a DEVDase activity assay ([Figure S1](#mmc1){ref-type="supplementary-material"}E). Similarly, apoptotic death and caspase-3 activation were absent in *hace1*^--/--^ MEFs challenged with TNF plus cycloheximide (CHX) ([Figure 2](#fig2){ref-type="fig"}D; [Figure S1](#mmc1){ref-type="supplementary-material"}F), an inhibitor of the NF-κB-mediated survival pathway ([@bib54]). Importantly, re-expression of WT HACE1, but not E3 ligase-dead C876S HACE1, restored TNF/ActD- as well as TNF/CHX-induced cell death in *hace1*^--/--^ MEFs ([Figures 2](#fig2){ref-type="fig"}E and 2F). SMAC mimetic drugs such as BV6 induce intrinsic apoptosis by blocking the inhibitor of apoptosis (IAP) proteins downstream of TNFR1 ([@bib58], [@bib60]). We therefore used this model as an additional trigger of TNF-induced apoptotic cell death. Baseline cIAP1 and XIAP expression levels before and after TNF stimulation were comparable in control and *hace1*^--/--^ MEFs ([Figure S1](#mmc1){ref-type="supplementary-material"}G). As expected, we observed TNF/BV6-induced cell death in control MEFs; by contrast, *hace1*^--/--^ MEFs again were resistant to apoptosis induced by TNF and BV6 ([Figure S1](#mmc1){ref-type="supplementary-material"}H). These results show that TNFR1-induced apoptosis depends on HACE1.

To test whether HACE1 also regulates TNFR1-mediated apoptosis in vivo, we first challenged control and *hace1*^--/--^ mice with recombinant murine TNF. *Hace1*^--/--^ mice were completely resistant to TNF-induced death and systemic inflammation, as determined by the liver injury markers ALT and AST ([Figures 3](#fig3){ref-type="fig"}A--3C). To extend these data to additional in vivo models, we next challenged mice with lipopolysaccharide (LPS)/D-Gal, which induces liver damage and death in WT mice, but not in TNFR1 mutant mice ([@bib45]). *Hace1* knockout mice were, to a large extent albeit not completely, resistant to LPS/D-Gal-induced liver damage and apoptotic death ([Figures 3](#fig3){ref-type="fig"}D--3F). These in vivo data indicate that *hace1* deficiency renders mice resistant to apoptotic liver damage and death downstream of TNFR1.

HACE1 Is a Gatekeeper of Apoptotic versus Necroptotic Cell Fate {#sec2.3}
---------------------------------------------------------------

In the condition where both NF-κB and caspase activation are either genetically or pharmacologically blocked, TNF stimulation may result in a non-apoptotic form of cell death termed necroptosis ([@bib8], [@bib9], [@bib13], [@bib17]). To determine whether loss of HACE1 also interferes with TNF-induced necroptosis, WT and *hace1*^--/--^ MEFs were pre-treated with the pan-caspase inhibitor Z-Val-Ala-Asp-fluoromethyl ketone (Z-VAD) and then stimulated with TNF/ActD to induce cell death. We observed that both WT and *hace1*^--/--^ MEFs are comparably sensitive to necroptosis triggered by TNF/ActD/Z-VAD ([Figure 4](#fig4){ref-type="fig"}A). These findings also were confirmed using TNF/CHX/Z-VAD as an alternative necroptotic drug combination ([Figure 4](#fig4){ref-type="fig"}A). Of note, treatment with Z-VAD alone or in combination with either ActD or TNF did not induce cell death in control or *hace1*^--/--^ MEFs ([Figures S1](#mmc1){ref-type="supplementary-material"}D and [S2](#mmc1){ref-type="supplementary-material"}A).

Two kinases, RIP1 and RIP3, mediate necroptotic cell fate downstream of TNFR1 ([@bib9], [@bib13]). Pre-treatment with the specific RIP1 kinase inhibitor necrostatin 1 (Nec-1) ([@bib14]) reverted necroptotic cell death in both control and *hace1*^--/--^ MEFs ([Figure 4](#fig4){ref-type="fig"}A). We next generated *hace1 ripk3* double-knockout (*hace1*^--/--^ *ripk3*^--/--^) MEFs to genetically determine the contribution of RIP3 on cell death in *hace1*^--/--^ MEFs. These double-mutant cells exhibited growth curves comparable to control MEFs ([Figure S2](#mmc1){ref-type="supplementary-material"}B). Importantly, whereas *hace1*^--/--^ MEFs were sensitive to necroptosis, *hace1*^--/--^ *ripk3*^--/--^ MEFs were resistant to necroptotic death ([Figure 4](#fig4){ref-type="fig"}B). Thus, HACE1 is required for TNF-induced NF-κB activation and apoptosis induction, but it is dispensable for the necroptotic response following TNFR1 stimulation.

HACE1 Mediates TRAF2 Ubiquitylation within the TNFR1-Receptor Complex {#sec2.4}
---------------------------------------------------------------------

To identify molecular targets of HACE1 that could explain impaired NF-κB activation and defective apoptosis downstream of TNFR1, we established a HACE1-dependent in vitro ubiquitylation assay using hemagglutinin (HA)-ubiquitin, the ubiquitin-activating E1 enzyme, and multiple E2 enzymes. The most efficient E2 for HACE1 E3 ligase activity was found to be Ubc13 ([Figure S3](#mmc1){ref-type="supplementary-material"}A). Using recombinant HACE1, Ubc13, the E1 enzyme, and HA-ubiquitin, we then performed in vitro ubiquitylation assays on microchips spotted with \>9,000 natively folded human proteins. Intriguingly, our microchip array data revealed multiple HACE1 ubiquitylation targets, many of which had been annotated previously to the TNFR1/NF-κB-signaling pathway ([Figures S3](#mmc1){ref-type="supplementary-material"}B and S3C). Using in vitro ubiquitylation assays, we confirmed that HACE1 directly ubiquitylates all targets tested (not shown). Intriguingly, among the substrates we found TRAF2.

Previous reports indicated that TRAF2 plays a pivotal role in driving NF-κB and JNK activation and inhibiting necroptosis after stimulation with TNF. This function is modulated by K63-linked ubiquitylation of TRAF2 ([@bib27], [@bib31], [@bib32], [@bib44], [@bib67]). To identify the nature of TRAF2 ubiquitylation mediated by HACE1, we performed an in vitro ubiquitylation assay. We found that HACE1 directly catalyzes K63-linked ubiquitylation of TRAF2 ([Figure S4](#mmc1){ref-type="supplementary-material"}A). Importantly, HACE1 is essential for this particular modification: lack of HACE1 led to the abrogation of TNF-driven K63-linked ubiquitylation of TRAF2 ([Figure S4](#mmc1){ref-type="supplementary-material"}B). We failed to detect TNF-induced K48-specific ubiquitylation of TRAF2 in control and *hace1*^--/--^ MEFs ([Figure S4](#mmc1){ref-type="supplementary-material"}C) as well as in in vitro ubiquitylation assays (not shown). Defective ubiquitylation was restored in *hace1*^--/--^ MEFs reconstituted with WT HACE1, but not in the E3 ligase-defective HACE1 C876S mutant ([Figure S4](#mmc1){ref-type="supplementary-material"}D). Similar to *hace1*^--/--^ MEFs, RNAi-mediated downregulation of HACE1 in WT MEFs impaired ubiquitylation of TRAF2 following TNF stimulation ([Figure S4](#mmc1){ref-type="supplementary-material"}E). These data indicate that HACE1 is a key regulator of K63-linked ubiquitylation of TRAF2.

Activation of TNFR1 induces rapid formation of a TRAF2-containing plasma membrane-bound signaling complex (complex I) ([@bib36]). Within complex I, K63 ubiquitylation of TRAF2 has been previously associated with the ability to activate NF-κB and to induce JNK signaling ([@bib19], [@bib32], [@bib33], [@bib66]). Endogenous HACE1 associated with TRAF2, an interaction that was markedly enhanced upon TNF stimulation ([Figures S5](#mmc1){ref-type="supplementary-material"}A and S5B). Moreover, endogenous HACE1 co-immunoprecipitated with TNFR1 in WT MEFs, an interaction that appears to be constitutive ([Figures S5](#mmc1){ref-type="supplementary-material"}C and S5D). Cell surface expression of TNFR1 in *hace1*^--/--^ MEFs was comparable to that in control cells ([Figure S5](#mmc1){ref-type="supplementary-material"}E). Immunoprecipitation of complex I using FLAG-tagged human TNF ([@bib36]) showed that all the essential components of complex I, such as IKKα, IKKγ, TRAF2, as well as RIP1, were recruited to the activated TNFR1 in both control and *hace1*^--/--^ MEFs ([Figure 5](#fig5){ref-type="fig"}A; [Figure S5](#mmc1){ref-type="supplementary-material"}C). RIP1 kinase appeared to be normally phosphorylated and ubiquitylated within complex I ([Figure 5](#fig5){ref-type="fig"}A; [Figures S5](#mmc1){ref-type="supplementary-material"}F and S5G). Serial immunoprecipitation experiments, carried out to pull down TRAF2 from the TNF-activated complex I ([@bib35]), showed a marked defect in K63 ubiquitylation of TRAF2 in *hace1*^--/--^ versus control MEFs ([Figure 5](#fig5){ref-type="fig"}B; [Figure S5](#mmc1){ref-type="supplementary-material"}H). Thus, loss of HACE1 has no apparent effect on the assembly of complex I; however, HACE1 is essential for the ubiquitylation of complex I-associated TRAF2.

Impaired Assembly of the Caspase-8 Activation Complex {#sec2.5}
-----------------------------------------------------

Following initial formation of complex I, TNFR1 stimulation results in the assembly of a secondary cytoplasmic complex, termed complex II ([@bib36]), which drives caspase-8-dependent apoptotic cell death ([@bib13], [@bib25], [@bib40], [@bib65]). To investigate whether the observed resistance of *hace1*^--/--^ MEFs to TNF-induced apoptosis originates from defective complex II formation, we analyzed the assembly of the apoptotic complex II following TNF/ActD stimulation. In *hace1*^--/--^ MEFs, the association of TRAF2 with FADD ([Figure 5](#fig5){ref-type="fig"}C), as well as its TNF stimulation-dependent association with RIP1 kinase ([Figure 5](#fig5){ref-type="fig"}D), was severely impaired. Further in vitro assays using recombinant proteins showed that TRAF2 and FADD interaction depends on ubiquitylation of TRAF2 ([Figure S6](#mmc1){ref-type="supplementary-material"}A). Moreover, the recruitment of RIP1 kinase and caspase-8 to FADD also was severely affected ([Figure 5](#fig5){ref-type="fig"}E), demonstrating that loss of HACE1 expression results in defective assembly of the caspase-8-activating complex.

Loss of HACE1 does not impair necroptosis downstream of TNFR1 stimulation ([Figure 4](#fig4){ref-type="fig"}A). Necroptosis is mediated via the formation of complex II containing, among other proteins, FADD, caspase-8, and both RIP1 and RIP3 kinases. When caspase-8 is inactivated, RIP1 and RIP3 kinases together induce programmed necrosis ([@bib8], [@bib9], [@bib13], [@bib17], [@bib70]). As reported previously ([@bib63]), Z-VAD inhibition of caspase-8 in TNF/ActD-treated WT MEFs was associated with enhanced stability of the FADD/caspase-8/RIP1 kinase complex ([Figure 5](#fig5){ref-type="fig"}E; [Figure S6](#mmc1){ref-type="supplementary-material"}B). Intriguingly, the association of RIP1 kinase and caspase-8 with FADD was found to be virtually absent in *hace1*^--/--^ MEFs undergoing TNF/ActD/Z-VAD-triggered necroptosis ([Figure 5](#fig5){ref-type="fig"}E; [Figure S6](#mmc1){ref-type="supplementary-material"}B). In both control and *hace1*^--/--^ MEFs, RIP3 kinase binds to RIP1 kinase under necroptotic conditions ([Figure 5](#fig5){ref-type="fig"}F). This interaction is mirrored by the phosphorylation of the necroptotic downstream mediator MLKL ([Figure 5](#fig5){ref-type="fig"}G) ([@bib56]), indicating that induction of RIP1/RIP3-dependent necroptosis is not affected by the absence of HACE1. Interestingly, RIP1/RIP3 interactions can be detected, albeit at reduced levels, in *hace1*^--/--^ MEFs even under apoptotic conditions ([Figure 5](#fig5){ref-type="fig"}F). However, we failed to detect any association between the RIP1/RIP3 kinases and caspase-8 under necroptotic conditions in *hace1*^--/--^ MEFs treated with either TNF/ActD/Z-VAD or with TNF/BV6/Z-VAD ([Figures S6](#mmc1){ref-type="supplementary-material"}B and S6C) ([@bib20]). Importantly, we still observed RIP1 phosphorylation, a marker of RIP1 kinase activity and necroptotic pre-disposition ([@bib13]), in both control and *hace1*^--/--^ MEFs treated with TNF/ActD/Z-VAD ([Figure 5](#fig5){ref-type="fig"}E; [Figure S6](#mmc1){ref-type="supplementary-material"}B) or TNF/BV6/Z-VAD ([Figure S6](#mmc1){ref-type="supplementary-material"}C). Thus, loss of HACE1 expression impairs the assembly of the canonical complex II without any apparent effect on the formation and activity of the necrosome formed by RIP1 and RIP3 kinases and phosphorylation of MLKL.

Hace1-Deficient Mice Are Hyper-susceptible to DSS-Induced Colitis {#sec2.6}
-----------------------------------------------------------------

Our data so far showed that loss of HACE1 protects cells from TNF-induced apoptosis in vitro while leaving TNF-mediated RIP1/RIP3 kinase-dependent necroptosis intact. Since TNFR1, NF-κB, and RIP3 kinase recently have been implicated in intestinal homeostasis ([@bib18], [@bib42], [@bib65]), we tested whether HACE1 might play a role in gut inflammation. Naive *hace1*^--/--^ mice showed normal body weight ([Figure S7](#mmc1){ref-type="supplementary-material"}A), and morphological and flow cytometric analyses of the intestine of naive *hace1*^--/--^ mice did not reveal any overt alteration compared to WT littermates ([Figures S7](#mmc1){ref-type="supplementary-material"}B and S7C). However, when we challenged mice with dextran sodium sulfate (DSS), a chemical irritant that disrupts the intestinal epithelial barrier and induces colitis ([@bib12]), we observed markedly increased intestinal inflammation in *hace1*^--/--^ versus control *hace1*^+/+^ mice. *Hace1*^--/--^ mice suffered a more pronounced weight loss than WT mice when treated with DSS ([Figure 6](#fig6){ref-type="fig"}A), and histopathological analysis revealed markedly more severe inflammation, tissue destruction, and epithelial cell death in *hace1*^--/--^ mice compared to WT littermate controls ([Figure 6](#fig6){ref-type="fig"}B; [Figure S7](#mmc1){ref-type="supplementary-material"}D). In addition, *hace1*^--/--^ mice showed more severe diarrhea and increased intestinal bleeding (hemoccult test) compared to WT littermates ([Figures 6](#fig6){ref-type="fig"}C and 6D). Flow cytometric analysis of the immune system in the lamina propria revealed markedly increased infiltration of CD11b^+^ Gr-1^+^ Ly6G^--^ inflammatory monocytes in the intestines of *hace1*-deficient mice after treatment with DSS ([Figure 6](#fig6){ref-type="fig"}E), confirming the increased severity of intestinal inflammation in *hace1*^--/--^ compared to control WT mice.

Both NF-κB and TNFR1 pathways play fundamental roles in immunity. NF-κB acts downstream of surface receptors recognizing pro-inflammatory cytokines, including TNF itself, as well as pathogen-associated pattern receptors, which in turn leads to the expression of further inflammatory mediators ([@bib7]). On the other hand, NF-κB expression in epithelia such as the intestine plays a fundamental role in ensuring epithelial cell survival and in maintaining the structural integrity of mucosal surfaces ([@bib42]). Hace1 mRNA is expressed at comparable levels in a variety of immune cells as well as in intestinal epithelial cells ([Figure S7](#mmc1){ref-type="supplementary-material"}F). To discern in which cells HACE1 is acting to prevent severe colitis, we generated bone marrow chimeric mice lacking HACE1 exclusively in the immune system by transferring *hace1*-deficient bone marrow cells in lethally irradiated *hace1*-sufficient host mice. As T cells in the intestine are largely radioresistant, we used lymphopenic *rag2*^--/--^ mice as hosts (KO→*rag2*^--/--^) to prevent host-derived WT T cells to persist in the intestine, thus affecting the validity of the system. As a control group, we reconstituted irradiated *rag2*^--/--^ mice with WT bone marrow (WT→*rag2*^--/--^). Treatment of these chimeric mice with DSS revealed that the absence or presence of HACE1 in the immune system had no apparent effect on the development of colitis: both groups showed comparable weight loss ([Figure S7](#mmc1){ref-type="supplementary-material"}G) and similar recruitment of inflammatory cells to the intestinal lamina propria ([Figure S7](#mmc1){ref-type="supplementary-material"}H). These results indicate that the loss of HACE1 in radiosensitive immune cells is not responsible for the increased susceptibility of *hace1*^--/--^ mice to colitis.

Importantly, genetic inactivation of RIP3 kinase in *hace1*^--/--^ *ripk3*^--/--^ double-knockout mice and inactivation of TNFR1 in *hace1*^--/--^ *tnfr1*^--/--^ double-knockout mice completely rescued all parameters of the severe inflammatory phenotype in *hace1*^--/--^ mice to levels observed in WT littermates, including weight loss, tissue damage, death of epithelial cells, recruitment of inflammatory cells, as well as diarrhea and intestinal bleeding ([Figures 6](#fig6){ref-type="fig"}A--6E; [Figure S7](#mmc1){ref-type="supplementary-material"}D). Also, the expression of several pro-inflammatory mediators was upregulated in the colon of *hace1*^--/--^ mice; in *hace1*^--/--^ *tnfr1*^--/--^ and *hace1*^--/--^ *ripk3*^--/--^ mice the levels of these pro-inflammatory factors were again restored to levels detected in WT controls ([Figure S7](#mmc1){ref-type="supplementary-material"}E). The increased death of intestinal epithelial cells in DSS-treated *hace1*^--/--^ mice is probably the consequence of exaggerated immune activation and inflammation resulting from the preferential induction of TNF-driven necroptosis instead of apoptosis in the absence of HACE1 ([@bib43]). Of note, while others reported increased severity of colitis in *ripk3*^--/--^ ([@bib37]) and, to a lesser extent, in *tnfr1*^--/--^ mice ([@bib49], [@bib64]), in our hands single-knockout mice showed no change in weight loss compared to WT littermates ([Figure 6](#fig6){ref-type="fig"}F). The difference in *ripk3*^--/--^ mice might be due to the time point of analysis: [@bib37] reported a defect of *ripk3*^--/--^ animals in the recovery from DSS, while we focused on the earlier phase of tissue destruction during which enhanced necroptosis is known to be detrimental ([@bib18]). Together, our data show that the increased susceptibility of *hace1*-deficient mice to DSS-induced colitis depends on deregulated TNFR1 signaling and RIP3 kinase.

Hace1 Controls Colon Cancer via TNFR1 and RIP3 Kinase {#sec2.7}
-----------------------------------------------------

We initially identified HACE1 as a tumor suppressor gene downregulated in multiple cancers ([@bib1], [@bib68]). Since we observed increased intestinal inflammation, we next explored whether *hace1*^--/--^ mice are prone to develop colon cancer upon challenge with DSS and the genotoxic drug azoxymethane (AOM) ([@bib52]). Since *hace1*^--/--^ mice are particularly sensitive to DSS, we reduced the DSS treatment regimen to a level not sufficient to induce colon cancer in WT mice ([@bib12], [@bib51]). As expected using this low DSS dose, we failed to detect any tumors in control HACE1-expressing mice ([Figure 7](#fig7){ref-type="fig"}A). However, in *hace1*^--/--^ mice, we observed a markedly increased incidence of colon cancer as determined by colonoscopy or histopathological examination ([Figures 7](#fig7){ref-type="fig"}A and 7B). Colonic tumors in *hace1*^--/--^ mice show features consistent with adenomatous polyps as well as nuclear atypia, multiple mitotic figures, areas of carcinoma in situ, and focal invasion ([Figure 7](#fig7){ref-type="fig"}B). Most importantly, *hace1*^--/--^ *ripk3*^--/--^ as well as *hace1*^--/--^ *tnfr1*^--/--^ double-knockout mice were similar to WT mice and did not show AOM/DSS-induced colonic tumors ([Figures 7](#fig7){ref-type="fig"}A and 7B), indicating that simultaneous genetic inactivation of TNFR1 and RIP3 kinase considerably reduced colon cancer formation secondary to *hace1* deficiency. In conclusion, *hace1* deficiency predisposes to colonic inflammation and carcinogenesis, which is markedly alleviated by genetic inactivation of TNFR1 and RIP3 kinase.

Discussion {#sec3}
==========

Our results highlight HACE1 as a gatekeeper for TNFR1-mediated cell fates. Loss of HACE1 impairs TNFR1-mediated activation of NF-κB signaling and apoptosis in vitro and in vivo, but it does not inhibit TNFR1-dependent RIP1/RIP3-induced necroptosis. Moreover, our data show that enhanced inflammation and colon cancer in *hace1* mutant mice can be reverted by genetic inactivation of RIP3 kinase and TNFR1.

We propose the following scenario for HACE1-regulated NF-κB activation downstream of TNFR1. Loss of HACE1 does not impair formation of complex I at TNFR1; however, NF-κB and JNK activation are markedly impaired in *hace1*^--/--^ MEFs, a function dependent on its E3 ligase activity. Our results indicate that HACE1 expression is essential for K63 ubiquitylation of TRAF2 within complex I upon TNFR1 stimulation, which previously has been associated with the ability to activate the canonical NF-κB pathway and to induce JNK signaling ([@bib19], [@bib33], [@bib66]). Although NF-κB signaling is impaired, *hace1*^--/--^ MEFs do not undergo apoptosis in response to TNFR1 stimulation, which can be biochemically explained by the fact that *hace1*^--/--^ cells fail to form pro-apoptotic complex II. Moreover, our results show that TRAF2 ubiquitylation is required for TRAF2 to associate with the key death molecule FADD, which in turn nucleates the caspase-8 apoptosis effector complex. However, besides TRAF2, we found multiple additional HACE1 ubiquitylation targets that previously have been linked to cell death and signaling pathways downstream of TNFR1, suggesting that HACE1 could regulate TNFR1-regulated cell fate at various interception points.

Our in vitro and in vivo data indicate that necroptosis in *hace1* mutant cells is mediated via the RIP1/RIP3/MLKL pathway. Since we failed to detect formation of an intact necrosome, such death signals might progress independently of the canonical molecular necroptotic complex. Necroptosis in the context of *hace1* deficiency appears to occur without direct caspase-8 interaction with RIP1/RIP3 kinases, raising the possibility that alternative RIP1/RIP3 kinase complexes might exist when HACE1 is inactivated. Of note, in our experimental system, induction of necroptosis in *hace1* knockout MEFs still requires caspase inhibition via Z-VAD. Whether regulation of cFLIP ([@bib40]) could explain this remaining caspase dependency requires further exploration. Moreover, a feedback inhibition loop via RIP3 kinase activity has been reported recently in the control of caspase-8-mediated apoptosis ([@bib39]), suggesting complex interplays between the apoptotic and necroptotic death effector machineries.

We initially identified HACE1 as a candidate tumor suppressor gene in a child with Wilms' tumor ([@bib1], [@bib68]). In accord with its putative tumor suppressor function, we found HACE1 to be downregulated in multiple cancers ([@bib22], [@bib47]). That HACE1 can indeed suppress cancer was shown in *hace1* knockout mice that develop tumors of multiple tissues ([@bib68]). Since the TNFR1 and RIP1/RIP3 kinase pathway has been reported to induce oxidative stress and possibly alter cellular metabolism ([@bib9], [@bib13], [@bib17]), our results suggest that this activation pathway downstream of TNFR1 might not only trigger necroptosis but also could be involved in oncogenesis. Moreover, RIP1/RIP3 kinases downstream of TNFR1 have been implicated in a pro-inflammatory cascade in the intestine unleashed by SMAC mimetics or caspase-8 deficiency ([@bib26], [@bib59]), driven by the release of necroptosis-mediated damage-associated molecular pattern molecules (DAMPs) ([@bib15], [@bib24]). *Hace1* mutant mice indeed develop increased intestinal inflammation following epithelial injury and increased incidence of colon cancer. Importantly, genetic deletion of either RIP3 kinase or TNFR1 not only reversed the enhanced inflammation but also strongly reduced the development of colon cancer in *hace1* single-mutant mice. These data demonstrate that deregulation of the TNFR1-mediated RIP3 kinase signaling is a key driving principle of inflammation and subsequent colon cancer development controlled by HACE1.

Experimental Procedures {#sec4}
=======================

Mice and Study Approval {#sec4.1}
-----------------------

The mice, *hace1*^+/+^, *hace1*^--/--^, *hace1*^--/--^ *tnfr1*^--/--^, and *hace1*^--/--^ *ripk3*^--/--^ on a C57BL/6 background, were bred and maintained under specific pathogen-free conditions at the Institute of Molecular Biotechnology of the Austrian Academy of Sciences (IMBA) animal facility. For experiments, age- and sex-matched mice (8--12 weeks of age) were used. All animal experiments were approved by Austrian authorities, and mice were kept following the guidelines of Austrian animal laboratory law.

Cell Lines and Western Blots {#sec4.2}
----------------------------

MEFs derived from *hace1*^+/+^ and *hace1*^--/--^ mice were prepared as described previously ([@bib68]). MEFs were seeded at 2 × 10^6^ cells per 60-cm^2^ Petri dish and cultured in DMEM supplemented with 5% fetal calf serum (FCS) and 1% Pen-Strep (Sigma) in a 5% CO~2~ incubator. The next day, cells were treated with 10 ng/ml mouse TNF (3014, Immunotools), 1 μg/ml ActD-Mannitol (A-5156, Sigma), 5 μg/ml Z-VAD (Bachem), and 50 nM Nec-1 (N-9037, Sigma). In addition, cells were treated with 10 ng/ml mouse TNF (3014, Immunotools) and 10 μg/ml CHX (C1988, Sigma). Following the treatments, the cells were lysed in 1 ml ice-cold NP-40 buffer (10 mM Tris \[pH 8.0\], 150 mM NaCl, and 1% Nonidet P-40) supplemented with protease and phosphatase inhibitor tablets (11873580001 and 04906837001, Roche). The lysates were then centrifuged at 14,000 rpm for 10 min at 4°C. Immunoprecipitations were performed according to the manufacturer's protocol.

In Vivo Lethality Experiments {#sec4.3}
-----------------------------

For high-dose lethal TNF challenge, animals were injected via the tail vein with 450 μg/kg of purified endotoxin-free TNF (Immunotools) in 200 μl PBS (pH 6.8). For induction of hyper-acute shock, TNF was used at a dose of 5 μg/kg. LPS (L2880, Sigma) was administrated intraperitoneally (i.p.) at a concentration of 10 μg/kg. D-Gal (G0500, Sigma) was given to mice together with LPS at a concentration of 1 g/kg. Liver enzymes were assayed using the Cobas C111 system (Roche). For histology, livers were embedded in paraffin, sectioned, and stained with H&E.

*Listeria* Infections {#sec4.4}
---------------------

*Listeria monocytogenes* (strain LO28) was prepared for infection as described previously ([@bib50]). The bacterial suspension (500 μl) was injected into the peritoneum of 8- to 10-week-old male *hace1*^+/+^ and *hace1*^--/--^ littermate mice. Survival of infected mice was monitored for 10 days. For determination of the bacterial load, mice were euthanized 96 hr after infection and spleens were homogenized in PBS. Serial dilutions of homogenates were plated on Oxford agar plates and colonies were counted after growth at 37°C for 24 hr.

Statistics {#sec4.5}
----------

If not otherwise stated, all data are expressed as the means ± SD. Significance was assessed by Student's two-sided t test unless otherwise stated in the figure legends. For multiple comparisons, we used a two-way ANOVA test with a Bonferroni post-test. Differences with p values \<0.05 were considered as significant (^∗^p \< 0.05, ^∗∗^p \< 0.01, and ^∗∗∗^p \< 0.001).
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![HACE1 Is Essential for the TNFR1-NF-κB Response\
(A) *Hace1*^+/+^ and *hace1*^--/--^ MEFs were stimulated with murine TNF (10 ng/ml) to induce the activation of TNFR1 downstream pathways. β-actin protein levels are shown as controls. Results are representative of three independent experiments.\
(B) NF-κB activation of TNF (10 ng/ml) stimulated (+) and untreated (−) *hace1*^+/+^ MEFs, *hace1*^--/--^ MEFs, *hace1*^--/--^ MEFs re-expressing WT HACE1, and *hace1*^--/--^ MEFs re-expressing the E3 ligase-dead C876S mutant. Triplicate filter plate assays of nuclear extracts are shown as mean values ± SD. HACE1 expression and re-expression were confirmed by western blot.\
(C) Time course of interleukin-6 (IL-6) induction in *hace1*^+/+^ and *hace1*^--/--^ MEFs following TNF (10 ng/ml) stimulation. IL-6 concentration was determined by ELISA in triplicate (mean values ± SD).\
(D) In vivo *Listeria monocytogenes* infections in *hace1*^+/+^ and *hace1*^--/--^ mice. Four days after infection animals were sacrificed, spleen extracts were plated, and bacterial loads in each spleen were determined as colony-forming units (CFUs)/spleen. Data for individual mice are shown.\
(E) Kaplan-Meier survival curves of *hace1*^+/+^ and *hace1*^--/--^ mice after *Listeria* infections are shown (p \< 0.01).\
See also [Figure S1](#mmc1){ref-type="supplementary-material"}.](gr1){#fig1}

![Loss of *Hace1* Confers Resistance to TNF-Induced Apoptosis In Vitro\
(A and B) *Hace1*^--/--^ MEFs do not undergo apoptosis. Cell viability (A) and representative images (B) are shown for *hace1*^+/+^ and *hace1*^--/--^ MEFs treated for 8 hr with either TNF alone (10 ng/ml) or TNF + ActD (1 μg/ml). Cell viability was determined in quadruplicate cultures (mean values ± SD). For images, cells were stained with crystal violet. Magnifications are ×10.\
(C) Levels of cleaved caspase-8 (cC8), cleaved caspase-3 (cC3), total RIP1 kinase protein, and cleaved RIP1 kinase (cRIP1) in lysates from *hace1*^+/+^ and *hace1*^--/--^ MEFs treated with TNF + ActD for the indicated time points. GAPDH is shown as a loading control.\
(D) Cell viability of *hace1*^+/+^ and *hace1*^--/--^ MEFs untreated (control) or exposed for 8 hr to TNF alone or TNF + cycloheximide (CHX; 10 μg/ml). Mean survival (±SD) was determined in quadruplicate cultures.\
(E and F) Cell viability of *hace1*^--/--^ MEFs re-expressing WT HACE1 and *hace1*^--/--^ MEFs re-expressing the E3 ligase-dead C876S mutant left untreated (control) or treated for 8 hr with TNF alone and either TNF + ActD (E) or TNF + CHX (F). Mean survival (±SD) was determined in quadruplicate cultures. Results are representative of more than three independent experiments.\
See also [Figure S1](#mmc1){ref-type="supplementary-material"}.](gr2){#fig2}

![*Hace1*^--/--^ Mice Are Protected from TNFR1-Induced Lethality In Vivo\
(A--C) *Hace1*^--/--^ mice are protected from liver damage in response to a high-dose (450 μg/kg) TNF challenge. (A) Kaplan-Meier survival curves are shown for *hace1*^+/+^ and *hace1*^--/--^ mice after TNF injection (n = 6 mice per group, p \< *0.05*). (B) Serum AST and ALT levels served as markers for liver damage in littermate *hace1*^+/+^ and *hace1*^--/--^ mice following in vivo challenge with high-dose TNF. Data from pooled sera (n = 4 mice per group) are shown. (C) H&E staining of representative histological liver sections 9 hr after the TNF challenge is shown.\
(D--F) *Hace1*^--/--^ mice are protected from death in response to LPS/D-Gal (LPS 10 μg/kg and D-Gal 1 g/kg mouse, i.p.). (D) Kaplan-Meier survival curves of *hace1*^+/+^ and *hace1*^--/--^ littermates injected intravenously (i.v.) with a lethal dose of LPS/D-Gal (n = 10 mice per group, p \< 0.01). (E) H&E staining and active caspase-3 immunodetection on liver sections 7 hr after LPS/D-Gal injections are shown. (F) Serum AST and ALT levels served as markers for liver damage in littermate *hace1*^+/+^ and *hace1*^--/--^ mice following in vivo challenge with a lethal dose of LPS + D-Gal. Data from pooled sera (n = 5 mice per group) are shown.](gr3){#fig3}

![*Hace1*^--/--^ Mutant Cells Undergo Necroptotis\
(A) *Hace1*^+/+^ and *hace1*^--/--^ MEFs were treated with TNF (10 ng/ml), Z-VAD (5 μg/ml), and Nec-1 (50 nM) plus either ActD (1 μg/ml) or CHX (10 μg/ml) using the indicated combinations. Cell viability was determined in triplicates (mean values ± SD).\
(B) *Hace1*^+/+^, *hace1*^--/--^, and *hace1*^--/--^*ripk3*^--/--^ MEFs were treated with TNF (10 ng/ml), Z-VAD (5 μg/ml), Nec-1 (50 nM), and ActD (1 μg/ml). Cell viability was determined in quadruplicates (mean values ± SD). Results are representative of at least three independent experiments.\
See also [Figure S2](#mmc1){ref-type="supplementary-material"}.](gr4){#fig4}

![Complex I and Complex II Formation\
(A) *Hace1*^+/+^ and *hace1*^--/--^ MEFs were stimulated with FLAG-tagged human TNF (FLAG-hTNF, 50 μg/ml) for the indicated time points followed by an anti-FLAG immunoprecipitation to detect proteins associated with the activated TNFR1 (complex I). FLAG-immunoprecipitates (IPs) and input lysates were probed with antibodies to IKKα, RIP1 kinase, TRAF2, and TNFR1. RIP1 kinase ubiquitylation as well as phosphorylation (p-RIP1) are indicated.\
(B) Serial immunoprecipitation of TRAF2 from the activated TNFR1 complex. Western blots were probed to detect K63-ubiquitylated TRAF2.\
(C) Interactions of TRAF2 with FADD were determined in anti-TRAF2 IPs from TNF- (10 ng/ml) stimulated (+) and untreated (−) *hace1*^+/+^ and *hace1*^--/--^ MEFs.\
(D) RIP1/TRAF2 interactions in *hace1*^+/+^ and *hace1*^--/--^ MEFs were determined by western blot on TRAF2 IPs from TNF-stimulated (+) and untreated (−) MEFs.\
(E) *Hace1*^+/+^ and *hace1*^--/--^ MEFs were treated with TNF (10 ng/ml), ActD (1 μg/ml), Z-VAD (5 μg/ml), and Nec-1 (50 nM) for 90 min followed by immunoprecipitation of FADD to detect FADD-RIP1 kinase and FADD-caspase-8 interactions. Lysates were assayed for protein expression of RIP1, caspase-8 (C8), and FADD. Phosphorylated RIP1 kinase (p-RIP1) is indicated.\
(F) *Hace1*^+/+^ and *hace1*^--/--^ MEFs were stimulated (+) or untreated (−) with TNF (10 ng/ml), ActD (1 μg/ml), and Z-VAD (5 μg/ml). Lysates were immunoprecipitated with anti-RIP1 antibodies to detect RIP1/RIP3 kinase interactions.\
(G) *Hace1*^+/+^ and *hace1*^--/--^ MEFs were left untreated (−) or stimulated (+) with TNF (10 ng/ml), ActD (1 μg/ml), and Z-VAD (5 μg/ml). Western blots show levels of total and phosphorylated MLKL (p-MLKL) at the indicated time points.\
See also [Figures S3--S6](#mmc1){ref-type="supplementary-material"}.](gr5){#fig5}

![Deletion of RIP3 Kinase or TNFR1 Alleviates the Severe Colitis in *Hace1*^*--/--*^ Mice\
(A) Percentage body weight changes during 7-day administration of DSS (2.5%) in WT, *hace1*^--/--^, *hace1*^--/--^*ripk3*^--/--^, and *hace1*^--/--^*tnfr1*^--/--^ mice are shown.\
(B) Representative colonic histopathology (H&E staining) from WT, *hace1*^--/--^, *hace1*^--/--^*ripk3*^--/--^, and *hace1*^--/--^*tnfr1*^--/--^ mice after 7 days of treatment with DSS. Lower histology panels depict magnifications of the selected areas.\
(C and D) Diarrhea and blood scores of WT, *hace1*^--/--^, *hace1*^--/--^*ripk3*^--/--^, and *hace1*^--/--^*tnfr1*^--/--^ mice treated with DSS for the indicated time periods. Data are shown as mean values ± SD (n = 5 mice per group). The p values are relative to DSS-treated *hace1*^--/--^ versus all other genotypes (WT, *hace1*^--/--^*ripk3*^--/--^, and *hace1*^--/--^*tnfr1*^--/--^).\
(E) Myeloid cell recruitment to the colonic lamina propria of DSS-treated mice. Neutrophils were defined as CD11b^+^ Gr-1^+^ Ly6G^+^, inflammatory monocytes as CD11b^+^ Gr-1^+^ Ly6G^--^, and dendritic cells (DCs) as CD11b^+/--^ CD11c^lo/+^ Gr-1^--^. All data in (B)--(E) are from mice at day 7 after DSS administration. Values show average ± SEM. Results are representative of more than three independent experiments.\
(F) Body weight changes during 7-day administration of DSS (2.5%) in WT, *ripk3*^--/--^, and *tnfr1*^--/--^ mice (n = 5 per group).\
See also [Figure S7](#mmc1){ref-type="supplementary-material"}.](gr6){#fig6}

![Genetic Inactivation of *ripk3* or *tnfr1* Reverts the Sensitivity of *hace1*^--/--^ Mice to DSS + AOM-Induced Colon Cancer\
(A) Representative colonoscopies and incidence of colon cancer of *hace1*^+/+^, *hace1*^--/--^, *hace1*^--/--^*ripk3*^--/--^, and *hace1*^--/--^*tnfr1*^--/--^ mice (n = 5 mice per cohort) after 7 weeks of treatment with AOM + DSS. Arrow indicates tumor.\
(B) Colonic histopathology (H&E stainings) on tissues harvested 14 weeks after AOM-DSS challenge. Note the large adenoma in *hace1*^--/--^ mice, whereas no aberrant hyperplasias or adenomas were observed in *hace1*^+/+^, *hace1*^--/--^*ripk3*^--/--^, and *hace1*^--/--^*tnfr1*^--/--^ mice. Magnifications are ×10; inset magnification are ×40. Experiments were repeated two more times with similar cohort sizes and we always observed analogous results.](gr7){#fig7}

[^1]: Co-first author
